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Abstract 
Background: Previous work in HEK-293 cells demonstrated the importance of amino acid-induced mTORC1 trans-
location to the lysosomal surface for stimulating mTORC1 kinase activity and protein synthesis. This study tested 
the conservation of this amino acid sensing mechanism in human skeletal muscle by treating subjects with chloro-
quine—a lysosomotropic agent that induces in vitro and in vivo lysosome dysfunction.
Methods: mTORC1 signaling and muscle protein synthesis (MPS) were determined in vivo in a randomized con-
trolled trial of 14 subjects (10 M, 4 F; 26 ± 4 year) that ingested 10 g of essential amino acids (EAA) after receiving 
750 mg of chloroquine (CHQ, n = 7) or serving as controls (CON, n = 7; no chloroquine). Additionally, differentiated 
C2C12 cells were used to assess mTORC1 signaling and myotube protein synthesis (MyPS) in the presence and 
absence of leucine and the lysosomotropic agent chloroquine.
Results: mTORC1, S6K1, 4E-BP1 and rpS6 phosphorylation increased in both CON and CHQ 1 h post EAA ingestion 
(P < 0.05). MPS increased similarly in both groups (CON, P = 0.06; CHQ, P < 0.05). In contrast, in C2C12 cells, 1 mM leu-
cine increased mTORC1 and S6K1 phosphorylation (P < 0.05), which was inhibited by 2 mg/ml chloroquine. Chloro-
quine (2 mg/ml) was sufficient to disrupt mTORC1 signaling, and MyPS.
Conclusions: Chloroquine did not inhibit amino acid-induced activation of mTORC1 signaling and skeletal MPS in 
humans as it does in C2C12 muscle cells. Therefore, different in vivo experimental approaches are required for con-
firming the precise role of the lysosome and amino acid sensing in human skeletal muscle.
Trial registration NCT00891696. Registered 29 April 2009.
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Background
Various anabolic stimuli facilitate muscle growth through 
the stimulation of the mechanistic target of rapamy-
cin complex 1 (mTORC1). In particular, activation of 
mTORC1 results in the induction of a signaling cascade 
that promotes the enhancement of protein initiation and 
translation [1–3]. While ingestion of protein or amino 
acids has been shown to result in increases in skeletal 
muscle protein synthesis in animal and human models 
[4–8], the precise mechanism(s) through which amino 
acids activate mTORC1 is less understood.
An increase in amino acid availability within the cell 
shifts the environment from a catabolic to an anabolic 
state. During catabolism, mTORC1 is inactive. The inac-
tive state of mTORC1 coincides with an upregulation of 
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autophagy through the lysosomal degradation pathway 
[9]. This increase in autophagy provides amino acids that 
may be converted into energy-yielding substrates during 
periods of low energy availability. Conversely, during the 
anabolic state, autophagy is suppressed, and the lysosome 
becomes an integral component in the synthesis of new 
proteins via mTORC1 activation [10].
Recent work in human embryonic kidney cells (HEK) 
has identified important molecular processes through 
which amino acids are “sensed” at the cellular level. 
During periods of low energy availability, mTORC1 is 
inactive and the GATOR1 protein complex serves as a 
GTPase-activating protein (GAP) to inactivate Rag A/B 
proteins located on the surface of the lysosome. These 
Rag proteins, in a GDP-bound state, prevent localization 
of mTORC1 to the lysosome [11, 12]. On the other hand, 
increased amino acid availability within the cell activates 
the amino acid sensing machinery upon introduction of 
the amino acids into the lysosome. The arginine trans-
porter SLC38A9 may be the first amino acid transporter 
identified that signals availability of amino acids to the 
lysosome [13, 14]. Once amino acids are “sensed” by the 
cell, GATOR1 action is inhibited via GATOR2 activation 
through a mechanism by which Sestrin 2 serves as a leu-
cine sensor [15, 16]. This allows for the Rag proteins to 
switch from a GDP-bound state to a GTP-bound state. 
The Rag A/C heterodimer becomes active in the GTP-
bound state and then recruits the mTORC1 complex to 
bind to the lysosome. This colocalization of mTORC1 
and the lysosome initiates the mTORC1 signaling cas-
cade [12] resulting in a stimulation of protein synthesis 
during amino acid sufficiency [17].
The mechanism of amino acid sensing via mTOR/
lysosomal colocalization was discovered in HEK cells. 
Whether a similar mechanism is responsible for activat-
ing mTORC1 in the presence of increased amino acid 
availability within human skeletal muscle is not known. A 
substantial amount of research has demonstrated the link 
between protein or amino acid ingestion and increases 
in skeletal muscle protein synthesis. To this point, these 
studies have been descriptive in nature. This proposed 
mechanism could shed light on the long-sought mecha-
nism bridging the gap between amino acid ingestion 
and mTOR pathway-activated protein synthesis. Cur-
rently there is evidence to suggest that colocalization of 
mTORC1 and the lysosome occurs in skeletal muscle in 
the presence of amino acids [18, 19] We were intrigued 
by the drug chloroquine, a lysosomotropic agent that 
causes lysosomal dysfunction in  vivo, as to whether it 
would be a useful pharmacological intervention to test 
the role of the lysosome in amino acid sensing in human 
skeletal muscle. Therefore, we hypothesized that amino 
acid-induced activation of mTORC1 signaling and mus-
cle protein synthesis would be inhibited by the admin-
istration of chloroquine. To test our hypothesis, we 
employed a randomized controlled human trial followed 




We recruited fourteen healthy, men and women 
18–40 years of age for this randomized clinical trial. Par-
ticipant characteristics are shown in Table 1.
The participants were recruited through flyers, news-
paper advertisements, and word of mouth (Fig.  1). Par-
ticipants were required to be healthy, only recreationally 
active, nonsmoking, with a body mass index < 30. Par-
ticipants were screened at the Institute for Translational 
Sciences-Clinical Research Center (ITS-CRC) at the Uni-
versity of Texas Medical Branch. The screening included: 
laboratory tests (complete blood count with differential, 
liver and kidney function tests, coagulation profile, fast-
ing blood glucose, hepatitis B and C screening, HIV test, 
thyroid stimulating hormone, lipid profile, urinalysis, and 
drug screening), clinical history with physical exam, and 
a dual-energy X-ray absorptiometry (DXA) scan (Lunar 
iDXA, GE Healthcare, Madison, WI) for measuring lean 
and fat mass. All participants provided written informed 
consent before enrollment in the study. The study was 
approved by the Institutional Review Board of the Uni-
versity of Texas Medical Branch, and is in compliance 
with the Declaration of Helsinki as revised in 1983.
Study design
In a randomized controlled trial, subjects were rand-
omized to either a control or treatment group, control 
(N = 7 Con) or chloroquine (N = 7 CHQ). Both groups 
completed an identical experimental trial (see below) 
with the exception of the treatment group receiving 
Table 1 Subject characteristics
Data are mean ± SEM
N Gender Age, years BMI, kg/m2 Fat % Lean Mass, kg
CON 7 5 M, 2F 24.9 ± 1.5 22.0 ± 0.8 21.3 ± 2.1 47.4 ± 2.9
CHQ 7 5 M, 2F 26.9 ± 1.9 23.0 ± 1.0 22.0 ± 2.2 50.3 ± 4.1
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chloroquine prior to ingesting EAA (Fig.  2). One sub-
ject per group was excluded from the results due to an 
inability to retrieve a muscle sample during the third 
biopsy. Enrolled participants reported to the ITS-
CRC at ~ 1800  h the night before the study. Partici-
pants refrained from exercise for at least 48  h prior to 
admission. Participants were fed a standardized din-
ner (10  kcal/kg of body weight; 60% carbohydrate, 20% 
fat, and 20% protein) and a snack at 2100 h (5 kcal/kg of 
body weight; 60% carbohydrate, 20% fat, and 20% pro-
tein), and asked to sleep in the UTMB CRC. After 2300 h, 
they were allowed only water until the completion of the 
experimental trial. CHQ subjects ingested a 250 mg dose 
of chloroquine at 2000 h the night before the study and 
a 500  mg dose the next morning following commence-
ment of the stable isotope tracers consistent with De feo 
et al. [20]. Control subjects received nothing. No placebo 
pill was given as it seemed unnecessary as the subjects 
remained in bed for the duration of the study and could 
not manipulate the outcome measures of this study via a 
placebo effect.
Experimental protocol
On the morning of the experimental trial, an 18G poly-
ethylene catheter was inserted into a vein in the ante-
cubital space in order to begin the primed, constant 
infusion (~ 10  h) of L-[ring-13C6] phenylalanine and 
L-[15N] phenylalanine (Sigma-Aldrich, St. Louis, MO, 
USA). A background blood sample was taken prior to 
commencement of the isotope infusion. The priming 
dose for the labeled phenylalanine was 2 μmol∙kg−1 while 
the infusion rate was 0.05 μmol  kg−1  min−1. A retrograde 
catheter was inserted into a heated hand vein on the con-
tralateral arm so that arterialized blood may be taken for 
sampling. Muscle biopsies were performed on the lat-
eral aspect of the vastus lateralis for the determination 
of resting mixed muscle fractional synthesis rate (FSR) at 
2 h and 4.5 h following stable isotope infusion initiation. 
All biopsies were taken with a 5  mm Bergström biopsy 
needle under sterile procedure and local anesthesia (1% 
lidocaine). The EAA beverage was consumed follow-
ing the second biopsy with biopsies three and four per-
formed 60  min and 120  min post ingestion respectively 
in order to measure post EAA mTORC1 signaling and 
protein synthesis. A single incision was used for both pre 
EAA muscle biopsies while a second incision was used 
for the two post EAA biopsies. Multiple sampling from 
the same area was limited by separating the incisions 
by ~ 7  cm. Biopsies taken from the same incision were 
angled ~ 5  cm from the previous one. This method has 
been utilized in both our lab [21, 22] and as well as others 
[23, 24]. Muscle tissue was immediately blotted, frozen in 
liquid nitrogen and stored at − 80 °C until analysis. Blood 
samples were collected during the resting (0, 89, 95, 105, 
115, 125, 135, 150 min) and post-ingestion (0, 15, 30, 45, 
60, 75, 90, 105, 120 min) time periods for the determina-
tion of blood L-[ring-13C6] phenylalanine enrichment and 
amino acid concentrations. The infusion study concluded 
with the fourth muscle biopsy at which time the partici-
pants were fed a standard meal.
Essential amino acid beverage
The EAA beverage was consumed following biopsy two. 
The ingested EAA were dissolved in 300  mL of Fresca® 
and enriched (8%) with L-[ring-13C6] and L-[15N] phe-
nylalanine to maintain isotopic steady state in arterial-
ized blood. The composition of the beverage is shown in 
Table 2.
Muscle protein turnover
Enrichments of free L-[ring-13C6]Phenylalanine, and 
L-[15N]Phenylalanine in blood and tissue fluid were 
measured by gas chromatography–mass spectrom-
etry (GC–MS) after addition of appropriate internal 
standards and precipitation of blood and tissue pro-
teins with sulfosalycilic acid, extraction with cation 
exchange chromatography, and tert-butyldimethylsilyl 
derivatization (t-BDMS). Correction for skewed iso-
topomer distribution and overlapping spectra were 
Fig. 1 Consort flow diagram for study recruitment
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performed as previously described [24]. The incorpora-
tion of L-[ring-13C6]Phenylalanine in the mixed mus-
cle proteins was measured after protein extraction and 
hydrolysis, amino acid extraction with cation exchange 
chromatography, TBDMS derivatization, and GC–MS 
analysis [25, 26].
Calculation of muscle protein synthesis
Muscle proteins and intracellular free amino acids were 
extracted from biopsy samples as previously described 
[21]. Bound muscle and intracellular free concentra-
tions were calculated with the internal standard method 
using tracer enrichments for L-[ring-13C6] phenylalanine, 
L-[15N] phenylalanine and appropriate internal standards 
via GC–MS (6890 Plus CG, 5973N MSD, 7683 autosa-
mpler, Agilent Technologies, Palo Alto, CA). Measure-
ments were determined as previously described [24, 26]. 
Mixed-muscle protein-bound phenylalanine enrichment 
was analyzed by GCMS after protein hydrolysis and 
amino acid extraction, [27] using the external standard 
curve approach [28]. The FSR of mixed muscle proteins 
was calculated from the incorporation rate of L-[ring-
13C6] phenylalanine into the mixed muscle proteins, and 
the free-tissue phenylalanine enrichment where ΔEP/t is 
Fig. 2 Schematic of randomized experimental protocol. Participants ingested 10 g EAA following biopsy two. The small arrows represent blood 
draws whereas the large arrows represent biopsies. EAA, essential amino acids. FSR, fractional synthesis rate. FBR, fractional breakdown rate. n = 7 
(CON), 7 (CHQ)
Table 2 Composition of the essential amino acid solution
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the slope of the straight line that fits the protein-bound 
phenylalanine enrichment across two sequential biop-
sies, t is the time interval encompassing the two biop-
sies,  EM(1), and  EM(2) are the phenylalanine enrichments 
(tracer/tracee) in the free muscle pool in the two biop-
sies. The results are presented as %/h. Phenylalanine is 
used because it is an essential amino acid that is not oxi-
dized in the muscle tissue. Thus, phenylalanine utiliza-
tion in the muscle is an index of muscle protein synthesis 
seen in the following equation:
Calculation of muscle protein breakdown
Muscle protein fractional breakdown rate (FBR) was 
measured with phenylalanine tracers using the precur-
sor-product method [24]. The method requires measure-
ment of intracellular free phenylalanine enrichment at 
steady-state and after 1 h of tracer decay. Frequent arteri-
alized blood sampling during that 1 h period is necessary 
for tracking the decay of blood enrichment. To measure 
FBR at baseline, the L-[ring-13C6] phenylalanine enrich-
ment at 4  h was used as the plateau enrichment and 
L-[15N] Phenylalanine enrichment at 4  h was used for 
the 1 h decay enrichment. FBR was calculated using the 
formula:
where EA(t) and EM(t) are the arterialized and muscle 
free enrichments at time t, and t1 and t2 are two time 
points. P = EM/(EA − EM) at plateau, EA and EM are 
enrichments in the arterial pool and muscle intracellular 
pool, respectively, and QM/T is the ratio of free to bound 
phenylalanine in muscle.
Whole body proteolysis
Whole body proteolysis was measured by dividing the 
L-[ring-13C6] phenylalanine tracer infusion rate by the 
blood L-[ring-13C6] phenylalanine enrichment (tracer to 
tracee ratio) at each given time point [29].
Western blot analysis
Phosphorylation of mTORC1, 4E-BP1, S6K1, and rpS6 
was measured using western blot techniques as previ-
ously described [22]. 50 μg of protein from each sample 
was loaded in duplicate onto a 7.5% or 15% polyacryla-
mide gel (Criterion; Bio-Rad) and subjected to electro-
phoresis at 150 V for 70 min. Following electrophoresis, 
proteins were transferred to a polyvinylidene difluoride 
membrane (Bio-Rad) that were then blocked in 5% 
non-fat dried milk. Membranes were incubated with a 
FSR = (�Ep/t)/[(EM(1) + EM(2))/2] · 60 · 100
FBR = �EM/[p
∫
EA(t)dt − (1+ p)
∫
EM(t)dt] · (QM/T )
primary antibody overnight at 4 °C. The following rabbit 
polyclonal primary antibodies (Cell Signaling, Beverley, 
MA) were used: mTOR  (Ser2448), S6K1  (Thr389), 4EBP1 
 (Thr37/46), and ribosomal protein S6  (Ser240/244). Blots 
were incubated with secondary antibody (Amersham 
Bioscience) washed, and then a chemiluminescent solu-
tion (ECL plus; Amersham BioSciences, Piscataway, NJ, 
USA) was administered. Optical density measurements 
were then obtained with a digital imager (Bio-Rad) so 
that a densitometric analysis (Quantity One software, 
version 4.5.2; Bio-Rad) could be performed. Follow-
ing detection of the phosphorylated protein, blots were 
stripped of primary and secondary antibodies and then 
re-probed for other proteins. All data is expressed rela-
tive to the internal standardized rodent skeletal muscle 
control used to normalize across blots.
Cell culture
Murine C2C12 myoblasts were obtained from American 
Type Culture Collection (Manassas, VA) and cultured 
on 0.1% gelatin‐(Sigma‐Aldrich, St. Louis, MO) coated 
6-well cultureware plates in growth media (high‐glucose 
Dulbecco’s modified Eagle medium supplemented with 
10% fetal bovine serum, 50 U of penicillin/mL, 50 μg of 
streptomycin/mL; Invitrogen, Carlsbad, CA). The cells 
were incubated in an atmosphere of 5% CO2/95% air 
at 37  °C. At ~ 90% confluency, differentiation medium 
(low‐glucose Dulbecco’s modified Eagle medium sup-
plemented with 2% horse serum, 50 U of penicillin/mL, 
50 μg of streptomycin/mL; Invitrogen, Carlsbad, CA) was 
added to cultures for approximately 5  days to allow for 
formation of multinucleated myotubes.
Cell culture experimental design
mTORC1 signaling
At the outset of the experiment, myotubes were nutri-
ent starved for 8  h in starvation media of HEPES‐buff-
ered saline with no leucine (HBS, 20  mmol/L HEPES/
Na, 140  mmol/L NaCl, 2.5  mmol/L MgSO4, 5  mmol/L 
KCl, and 1  mmol/L CaCl2; pH 7.4; Sigma‐Aldrich). For 
each 6-well plate, two wells were designated “control 
(Con)” and allowed to be starved for an additional 70 min 
in starvation media for a total of 9  h and 10  min. Two 
wells were designated “leucine only (Leu)”. These wells 
were starved for a total of 9  h and then administered 
1  mM leucine for 10  min. Lastly, two wells were desig-
nated “chloroquine plus leucine (Chq + leu)”. These wells 
were nutrient starved for 8  h and then administered 
2 mg/ml chloroquine for 60 min followed by 1 mM leu-
cine treatment for 10  min. The experimental procedure 
was repeated to reach a sample size of eight per group. 
All wells were washed with PBS between all treatment 
administrations. This specific protocol was developed 
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as a result of extensive pilot testing in order to properly 
optimize these experimental conditions. The 2  mg/ml 
dose was chosen following MTT cell viability assays.
Following treatments, myotubes were rinsed with 
PBS and each well scraped in ice‐cold extraction buffer 
(50 mmol/L Tris‐HCl, 250 mmol/L mannitol, 50 mmol/L 
NaF, 5  mmol/L Na pyrophosphate, 1  mmol/L EDTA, 
1  mmol/L EGTA, 1% Triton X‐100, 1  mmol/L DTT, 
1 mmol/L benzamidine, 0.1 mmol/L PMSF, 5 μg/mL soy-
bean trypsin inhibitor, pH 7.4). Samples were frozen in 
liquid nitrogen until analyzed.
To determine protein concentration, samples were 
thawed and vortexed three times and later sonicated for 
15  s. Protein concentrations were calculated using the 
Bradford Protein Assay (Smartspec Plus, Bio‐Rad, Hercu-
les, CA).
Myotube protein synthesis
MyPS was measured using the surface sensing of transla-
tion (SUnSET) technique as described by Goodman [30]. 
Cells were designated into two conditions, “nutrient rich” 
and “nutrient starve”. Within each condition, one subset 
was administered chloroquine while the other was not 
and thus served as controls. For the starvation condi-
tions, myotubes were starved and treated as described 
above for mTORC1 signaling with the exception of no 
leucine administration. Thus nutrient starve control cells 
were starved for 9 h in starvation media. Nutrient starve 
chloroquine cells were starved in starvation media for 
8 h, then for an additional hour in starvation media with 
2 mg/ml chloroquine. Cells were then administered 1 µM 
puromycin (Thermo Fisher Scientific, Wilmington, DE) 
for 30 min and collected as described above. The nutri-
ent rich condition entailed a 16 h serum starve (no horse 
serum) in low glucose DMEM followed by a 1 h starva-
tion in HEPES‐buffered saline containing 2 mg/ml chlo-
roquine for cells in that subgroup. Cells were then put 
back into DMEM while provided 1  µM puromycin for 
30  min and subsequently collected. The experimental 
procedure was repeated to reach a sample size of six per 
group. The experimental procedure here differs from the 
mTORC1 signaling procedure due to technical limita-
tions. It was not possible to detect a difference between 
control and a 10 min 1mM leucine administration using 
this method. We believe that a 1 mM bolus of leucine can 
result in mTORC1 pathway phosphorylation, yet it is not 
sufficient to promote activation of protein synthesis at a 
level necessary for detection. This is most likely due to 
the limited availability of amino acids required for gener-
ating new proteins as these cells are starved for 9 h with 
no amino acids and then given only leucine. Therefore a 
serum starve in low glucose DMEM was used to provide 
those amino acids in the nutrient rich groups.
Western blot analysis
Cell lysates were diluted (1:1) in a 2 × sample buffer mix-
ture (125 mmol/L Tris, pH 6.8, 25% glycerol, 2.5% SDS, 
2.5% β‐mercaptoethanol, and 0.002% bromophenol blue) 
and then boiled for 3  min at 100  °C. Equal amounts of 
total protein were loaded into each lane, and the samples 
were separated by electrophoresis at 150 V for 60 min on 
a 7.5% polyacrylamide gel (Criterion, Bio‐Rad). All sam-
ples were loaded in duplicate with a loading control and 
molecular weight ladder (Precision Plus, Bio‐Rad).
Following electrophoresis, the protein was transferred 
to a polyvinylidene difluoride membrane (Bio‐rad) at 
50 V for 60 min. Blots were blocked in 1% bovine serum 
albumin for 1  h for mTORC 1 signaling proteins or 
30 min for puromycin and then incubated with primary 
antibody overnight at 4  °C. The following rabbit poly-
clonal primary antibodies for mTORC1 signaling (Cell 
Signaling, Beverley, MA) were used, mTOR (Ser2448) 
and S6K1 (Thr389). The primary antibody for puromy-
cin protein synthesis was the mouse IgG2a monoclonal 
anti-puromycin antibody clone 12D10 (EMD Millipore, 
Billerica, MA).The following morning, secondary anti-
body (Amersham Bioscience Piscataway, NJ for mTOR 
signaling), or horseradish peroxidase conjugated anti-
mouse IgG Fc 2a antibody (Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA, USA for puromycin 
protein synthesis) was added for 1  h at room tempera-
ture. Blots were incubated in a chemiluminescent solu-
tion (ECL plus, Amersham BioSciences,) for 5  min and 
optical density measurements quantified using a digital 
imager (ChemiDoc, Bio‐Rad) and densitometric analysis 
was performed using Quantity One 4.5.2 software (Bio‐
Rad). Membranes were stripped using Restore Western 
Blot Stripping buffer (Pierce Biotechnology, Rockford, 
IL). Phosphorylation values were normalized to the load-
ing control.
Statistical analysis
All values are expressed as Mean ± SEM. Cell culture 
experimental data were modeled with t-tests to test dif-
ferences between groups. Clinical trial data were trans-
formed using the Box-Cox set of transformations to 
stabilize the variance and make the data approximately 
normally distributed. To test differences between groups, 
the data were modeled using an ANCOVA model with 
resting/baseline values as a covariate. The testing of dif-
ferences was thus accomplished through a t-test of the 
parameter indicating the difference between groups. 
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Comparisons with resting values were based on testing 
contrasts across time using a mixed model with subject 
as a random intercept term. All baseline comparisons 
were done using two-group t-tests. Fold changes were 
tested against baseline using a one-sample t-test. Signifi-





Descriptive characteristics for all subjects are shown in 
Table 1. The participants in both groups displayed simi-
lar lean mass, percent body fat and BMI (P > 0.05). The 
consort diagram for clinical trial enrollment is shown in 
Fig. 1.
Blood and muscle amino acid concentrations
Blood concentrations for leucine (Fig. 3A) were elevated 
from baseline (P < 0.05) for both treatment groups 60 min 
post ingestion. Leucine intracellular muscle concen-
trations were elevated in both groups at 1  h and at 2  h 
post ingestion compared to baseline (P < 0.05) while 1 h 
post ingestion was significantly different (P < 0.05) than 
2  h post ingestion for both groups (Fig.  3B). There was 
no difference between groups for either leucine meas-
ure (P > 0.05). Phenylalanine concentrations in the blood 
were elevated from baseline (P < 0.05) for CON from 30 
to 120 min post ingestion and CHQ from 15 to 90 min 
post ingestion (P < 0.05) (Fig. 3C). Phenylalanine intracel-
lular muscle concentrations were elevated in both groups 
at 1  h and at 2  h post ingestion compared to baseline 
(P < 0.05) while 1 h post ingestion was significantly higher 
than 2 h post ingestion for both groups (Fig. 3D). There 
was no difference between groups for either phenylala-
nine measure.
Muscle mTORC1 signaling
The phosphorylation status of mTORC1 (Ser2448) 
was significantly increased (P < 0.05) at 1  h post inges-
tion in both groups compared to baseline with only 
Fig. 3 Blood and Muscle Amino Acid Concentrations. Changes from 
rest in blood Leucine (A), muscle Leucine (B), blood Phenylalanine (C), 
and muscle Phenylalanine (D) at baseline and following ingestion of 
a 10 g EAA beverage. Data are mean ± SEM. N = 7 for both treatment 
groups. “a” different from resting values, P < 0.05. “b” difference 
between 1 h post and 2 h post, “c” difference between treatment 
groups, P < 0.05. CON, control. CHQ, chloroquine
▸
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CON significantly elevated at 2  h compared to baseline 
(Fig. 4A). S6K1 (Thr389) phosphorylation was elevated at 
1 h post ingestion for both groups. At 2 h post ingestion, 
CHQ showed a trend for increased S6K1 phosphoryla-
tion of P = 0.07 compared to baseline (Fig.  4B). 4E-BP1 
(Thr37/46) phosphorylation was significantly increased 
(P < 0.05) at 1 h post ingestion in both groups compared 
to baseline. CON 4E-BP1 phosphorylation was signifi-
cantly elevated at 2 h compared to baseline (Fig. 4C). The 
phosphorylation status of rpS6 (Ser240/244) was signifi-
cantly increased (P < 0.05) at 1  h post ingestion in both 
groups compared to baseline. Only CON rpS6 phos-
phorylation was significantly elevated at 2  h compared 
to baseline (Fig.  4D). There were no differences in total 
Fig. 4 Muscle mTORC1 Signaling. Western blot analyses of mTORC1 (A) and mTOR pathway-related proteins: S6K1 (B), 4EBP1 (C) and rpS6 (D), at 
baseline and following a 10 g EAA beverage. Data are mean ± SEM. N = 7 for both treatment groups. *Different from pre, P < 0.05. #trend difference 
from pre, P = 0.07. CON, control. CHQ, chloroquine
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protein abundance between groups at any time point for 
all measured proteins (P > 0.05).
Fractional synthetic rate
There was no difference between groups for mus-
cle protein synthesis at any time point (P > 0.05). Post 
EAA ingestion FSR was elevated from resting values 
for CHQ (P < 0.05) while CON showed a trend for an 
increase P = 0.06 (Fig. 5).
Fractional breakdown rate
There was no difference (P > 0.05) between groups for 
muscle protein breakdown at rest (Fig. 5).
Whole body proteolysis
There was no difference between groups at any time 
point (P > 0.05). Whole body proteolysis was significantly 
decreased from baseline in CON following EAA inges-
tion (P < 0.05) (Fig. 5).
Cell culture experiments
Myotube mTORC1 signaling and protein synthesis
The phosphorylation status of mTORC1 (Ser 2448) was 
significantly increased with 1 mM leucine administration 
(P < 0.05) compared to control and chloroquine + leu-
cine (Fig.  6A). The phosphorylation status of S6K1 
(Thr389) was significantly increased with 1 mM leucine 
administration (P < 0.05) compared to control and chlo-
roquine + leucine (Fig.  6B). MyPS was reduced in the 
presence of chloroquine for both the nutrient rich and 
nutrient starved conditions (P < 0.05) compared to their 
respective controls. There was no difference in protein 
synthesis between the two control conditions (nutrient 
rich vs. nutrient starve) (P = 0.095) nor was there a dif-
ference between control in the nutrient starvation state 
and chloroquine in the nutrient rich state (P = 0.478). 
Nutrient rich control was different compared to nutrient 
starved chloroquine (P < 0.05) (Fig. 6C).
Discussion
We conducted an in  vivo human clinical trial wherein 
we administered chloroquine prior to ingesting essential 
amino acids to test the effect of chloroquine on mTORC1 
signaling and protein synthesis. We found no effect of 
chloroquine on either outcome measure following EAA 
ingestion during the clinical trial.
The nutritional benefits of amino acid supplementa-
tion in humans have been investigated for many decades 
going at least as far back as the 1940s [32]. Since that 
time, it has become understood that amino acids pro-
mote protein synthesis [33]. Yet the mechanism(s) under-
lying amino acid activation of protein synthesis have 
Fig. 5 Fractional Synthetic Rate, Fractional Breakdown Rate, and Whole 
Body Proteolysis. A FSR (vastus lateralis) at baseline and for the two hour 
period post ingestion of the 10 g EAA beverage. Data are mean ± SEM. 
N = 7 for both treatment groups. *Different from rest, P < 0.05. #trend 
difference from pre, P = 0.06. FSR, fractional synthesis rate. CON, control. 
CHQ, chloroquine. EAA, essential amino acids. B FBR (vastus lateralis) 
for the 1 h period prior to ingestion of the 10 g EAA beverage. Data 
are mean ± SEM. N = 7 for both treatment groups. FBR, fractional 
breakdown rate. CON, control. CHQ, chloroquine. C Whole body 
proteolysis at baseline and for the two hour period post ingestion of 
the 10 g EAA beverage. Data are mean ± SEM. N = 7 for both treatment 
groups. *Different from pre, P < 0.05. CON, control. CHQ, chloroquine
Page 10 of 13Borack et al. Nutr Metab (Lond)           (2021) 18:61 
been elusive until recently. Work in HEK cells has dem-
onstrated the necessity of the interaction of the lysosome 
with the mTOR complex via a complex named Ragulator. 
The Ragulator protein complex resides on the surface of 
the lysosome. In the presence of amino acids, Ragulator 
recruits the Rag proteins in their GTP-bound state to the 
lysosomal membrane in order to dock with the mTOR 
complex and initiate mTOR signaling [34, 35]. A year 
later, [10, 36] revealed an additional component of amino 
acid sensing, the vacuolar H( +)-adenosine triphos-
phatase ATPase (v-ATPase). The v-ATPase was shown to 
provide a critical interaction with the scaffolding protein 
Ragulator during amino acid activation of mTOR signal-
ing [36]. Other players in the amino acid sensing mecha-
nism have since been identified. GATOR1 is an inhibitor 
of this pathway as it acts on the GTP-bound Rag proteins. 
GATOR2 works to inhibit GATOR1 in the presence of 
amino acids. Lastly the Sestrins are a family of proteins 
that interact with GATOR2 and are necessary for the 
colocalization of the lysosome and mTOR [37].
As all of the research described above was conducted 
in kidney cells, this current study sought to test the 
conservation of this amino acid sensing mechanism in 
human skeletal muscle. Settembre et  al. [38] demon-
strated reduced mTOR signaling with the inhibition of 
downstream target S6K1 using the drug chloroquine 
[38]. Chloroquine is a lysosomotropic agent that raises 
the internal pH of the lysosome. This change in pH 
causes lysosomal dysfunction and inhibition of lyso-
somal protein degradation [39]. Yu and Long [40] also 
demonstrated lysosomal/autophagy dysfunction through 
chloroquine administration in C212 cells [40]. This inhi-
bition resulted in a reduction in mTOR signaling under 
starvation conditions and an increase in signaling with 
amino acid supplementation, in the presence of chloro-
quine, although the treatment included thirteen separate 
amino acids [40].
To test the role of the lysosome in amino acid sensing 
in human muscle, we conducted a human trial utilizing 
a 10  g EAA solution that has been shown to enhance 
mTORC1 signaling and muscle protein synthesis dur-
ing previous studies [17, 41]. We found that chloroquine 
administration did not alter amino acid concentrations 
in the blood following EAA ingestion and did not inhibit 
mTORC1 activation. Similarly chloroquine administra-
tion did not prevent the EAA-induced increase in mus-
cle protein synthesis in our human subjects. Therefore, 
we could not confirm the validity of amino acid sensing 
through the lysosome in humans from this study. We also 
examined muscle protein breakdown and proteolysis to 
determine whether any chloroquine-mediated effects 
were present. Previous work has shown that a 750  mg 
dose of chloroquine (the dose used in the current study) 
is sufficient to reduce whole body proteolysis in humans 
[20]. In our study, we also found that the rate of whole 
body proteolysis was numerically less in the chloroquine 
group (e.g., 0.71 v 0.79 μmol/kg/min) at baseline, but this 
difference did not reach statistical significance. Amino 
acids have been shown to reduce both whole body as 
well as muscle protein breakdown [42, 43], and our data 
showed a similar response in the control group. Interest-
ingly, whole body proteolysis did not drop in response to 
EAA ingestion for the chloroquine group as it did for the 
control group which may indicate that chloroquine was 
having an impact on whole body proteolysis. Neverthe-
less, muscle protein breakdown was not altered by chlo-
roquine in our samples. Similarly Barrett et  al. did not 
witness a change in skeletal muscle protein breakdown 
during a 3  h chloroquine infusion into the forearm of 
human subjects [44]. Therefore, we are able to surmise 
two potential explanations for these results. The first is 
that inhibition of the lysosome by chloroquine can inhibit 
mTORC1 signaling and FSR in skeletal muscle as hypoth-
esized, but the dosage of chloroquine used in our study 
was not sufficient to alter muscle protein turnover. Chlo-
roquine is known to accumulate in certain tissues of the 
body, specifically the liver, spleen, kidney and lung. These 
organs were found to have chloroquine concentrations 
200–500 times that found in the blood [45]. Therefore, it 
is possible that the dosage for this study was insufficient 
to reach the levels necessary to interrupt lysosomal func-
tion within skeletal muscle. That would help to explain 
the disparity between our results at the whole body level 
versus at the muscle specific level as well as differences 
(See figure on next page.)
Fig. 6 Myotube mTORC1 signaling and protein synthesis. Cells were starved for 8 h in HEPES-buffered saline. Control was starved for an additional 
70 min in fresh HEPES. “Leucine” was starved for 60 min in fresh Hepes and 10 min in fresh Hepes with leucine. “Chloroquine + leucine” was starved 
in fresh HEPES with chloroquine for 60 min and 10 min in fresh HEPES with leucine. A Phosphorylation of mTORC1 at Ser 2448 in control, leucine 
(1 mM for 10 min), and chloroquine + leucine (2 mg/ml chloroquine for 60 min followed by 1 mM leucine for 10 min) conditions. Insert shows 
representative western blot for each condition. B Phosphorylation of S6K1 at Thr 389 (same conditions). Insert shows representative western blot for 
each condition. Data are mean ± SEM. N = 8 for both treatment groups. *Different from control, P < 0.05. &Different from chloroquine + leucine. Chq, 
chloroquine. C Western blot analyses of protein synthesis using the SUnSET technique. Nutrient Rich-Control and Chloroquine were serum starved 
for 16 h and nutrient starved for 1 h (2 mg/ml for Chloroquine group only) prior to 30 min puromycin (1 µM) exposure. Nutrient Starve groups were 
starved under the same conditions as described above for mTORC1 signaling prior to 30 min puromycin (1 µM) exposure. Data are mean ± SEM, 
N = 6. abcColumns with uncommon letters differ, P < 0.05
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between earlier studies performed in various cell lines, 
and our study performed in humans. A second possibility 
is that lysosomal disruption within human skeletal mus-
cle does not alter mTORC1 signaling and muscle protein 
turnover following amino acid ingestion in vivo. It is pos-
sible that mTORC1 signaling may remain intact following 
lysosomal disruption by an amino acid sensing mecha-
nism that is independent of the lysosome in humans. 
We acknowledge the chloroquine dosing as a limitation, 
however, administering larger doses was not an option 
as that would have been considered unsafe to our par-
ticipants (as determined by our study physician and local 
institutional review board).
Following completion of the clinical trial, we conducted 
in vitro experiments to test the effect of chloroquine on 
mTORC1 signaling and protein synthesis in C2C12 myo-
tubes. We found an increase in both mTORC1 and S6K1 
phosphorylation following ten minutes of 1  mM leu-
cine administration. This increase was not seen in cells 
provided 2  mg of chloroquine for 1  h prior to leucine 
administration. Therefore it would appear that mTORC1 
signaling is potentially hampered in muscle cells in 
the presence of chloroquine. While it is not possible to 
determine if lysosomal disruption is the sole cause of 
this diminished signaling, it does provide evidence that 
is comparable to that seen by others mentioned above 
[38, 40]. Protein synthesis was reduced by chloroquine 
regardless of nutrient condition. Therefore, we can ten-
tatively conclude from these data that this mechanism of 
amino acid sensing (i.e., mTORC1 translocation to the 
lysosomal membrane in response to amino acid availabil-
ity) is conserved in C2C12 skeletal muscle cells.
Conclusions
In conclusion, chloroquine did not inhibit amino acid-
induced activation of mTORC1 signaling and skeletal 
muscle protein synthesis in humans as it does in C2C12 
muscle cells. Therefore, different in  vivo experimental 
approaches are required for confirming the precise role 
of the lysosome and amino acid sensing in human skel-
etal muscle.
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